BidaskClub upgraded shares of Seres Therapeutics (NASDAQ:MCRB) from a sell rating to a hold rating in a research report released on Saturday.

Several other equities analysts have also issued reports on the stock. Cantor Fitzgerald set a $15.00 price target on shares of Seres Therapeutics and gave the stock a buy rating in a report on Thursday, November 8th. Oppenheimer set a $16.00 price target on shares of Seres Therapeutics and gave the stock a buy rating in a report on Friday, November 9th. ValuEngine raised shares of Seres Therapeutics from a hold rating to a buy rating in a report on Tuesday, November 6th. Chardan Capital reaffirmed a buy rating on shares of Seres Therapeutics in a report on Sunday, October 28th. Finally, Bank of America lowered shares of Seres Therapeutics from a neutral rating to an underperform rating in a report on Friday, August 3rd. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company’s stock. Seres Therapeutics presently has an average rating of Hold and an average price target of $13.81.

NASDAQ MCRB opened at $8.09 on Friday. The company has a debt-to-equity ratio of 0.85, a quick ratio of 2.04 and a current ratio of 2.04. Seres Therapeutics has a 12-month low of $5.64 and a 12-month high of $11.35. The firm has a market capitalization of $343.19 million, a price-to-earnings ratio of -3.66 and a beta of 0.61.

Seres Therapeutics (NASDAQ:MCRB) last released its quarterly earnings results on Thursday, November 8th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.57) by $0.03. Seres Therapeutics had a negative net margin of 515.16% and a negative return on equity of 1,584.66%. The business had revenue of $9.06 million for the quarter, compared to analyst estimates of $23.43 million. Sell-side analysts anticipate that Seres Therapeutics will post -2.41 EPS for the current year.

In other news, insider John G. Aunins sold 14,279 shares of the business’s stock in a transaction on Monday, October 15th. The shares were sold at an average price of $5.94, for a total transaction of $84,817.26. Following the sale, the insider now directly owns 103,811 shares of the company’s stock, valued at $616,637.34. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Roger Pomerantz sold 12,518 shares of the business’s stock in a transaction on Thursday, September 6th. The shares were sold at an average price of $9.10, for a total transaction of $113,913.80. Following the sale, the insider now directly owns 218,799 shares in the company, valued at $1,991,070.90. The disclosure for this sale can be found here. Insiders sold 69,634 shares of company stock worth $526,006 over the last ninety days. Corporate insiders own 37.10% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the company. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Seres Therapeutics during the second quarter valued at $117,000. Citadel Advisors LLC grew its holdings in shares of Seres Therapeutics by 48.0% during the third quarter. Citadel Advisors LLC now owns 31,400 shares of the biotechnology company’s stock valued at $239,000 after buying an additional 10,183 shares during the last quarter. Bank of America Corp DE grew its holdings in shares of Seres Therapeutics by 175.0% during the second quarter. Bank of America Corp DE now owns 36,489 shares of the biotechnology company’s stock valued at $314,000 after buying an additional 23,222 shares during the last quarter. Chicago Equity Partners LLC purchased a new stake in shares of Seres Therapeutics during the second quarter valued at $415,000. Finally, Schwab Charles Investment Management Inc. grew its holdings in shares of Seres Therapeutics by 18.8% during the second quarter. Schwab Charles Investment Management Inc. now owns 117,255 shares of the biotechnology company’s stock valued at $1,009,000 after buying an additional 18,562 shares during the last quarter. 77.86% of the stock is currently owned by hedge funds and other institutional investors.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology, which is in Phase III clinical study to treat multiply recurrent Clostridium difficile infection (CDI).

Featured Story: Short Selling Stocks and Day Traders

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.